阿尔茨海默病是最常见的痴呆症。据美国疾病控制和预防中心(CDC), 多达670万美国人患有老年痴呆症，预计到2060年，这一数字将翻一番，达到1400万人。
今天，我们推出了新的ATN简介，这是一个重要的里程碑。这项首创的研究结合了三种经过充分研究的血液生物标志物测试，以识别和评估与阿尔茨海默病相关的生物学变化——淀粉样蛋白斑、tau蛋白缠结和神经退行性病变（ATN）。
ATN Profile可在全国范围内使用，用于根据临床观察和认知筛查评估可能的阿尔茨海默病或其他认知障碍原因的患者。该测试旨在帮助缩短诊断和干预的时间。神经学家和其他医疗保健提供者可以订购这种测试，以帮助他们决定是否将病人转介到专家。
据Brian Caveney，医学博士，执行副总裁和总裁，早期发展研究实验室和首席医疗和科学官，“许多患者经历周围的阿尔茨海默氏病的风险的不确定性，这可能需要几个月甚至几年的诊断。更明确的测试，包括我们新的ATN简介，可以为病人，他们的亲人，以及在他们指导治疗和治疗过程中治疗医生提供客观的见解。”
在Labcorp，我们仍然致力于改善受阿尔茨海默氏症影响的人的健康和生活，并将继续投资于治疗和管理疾病的研究和药物开发。
Alzheimer’s disease is the most common form of dementia. According to the U.S. Centers for Disease Control and Prevention (CDC), as many as 6.7 million Americans are living with Alzheimer’s, a number that is expected to more than double to 14 million people by 2060.
Today, we marked a major milestone by launching our new ATN Profile. This first-of-its-kind profile combines three well-researched blood biomarker tests to identify and assess biological changes associated with Alzheimer’s disease – amyloid plaques, tau tangles and neurodegeneration (ATN).
The ATN Profile is available nationwide for use with patients being evaluated for possible Alzheimer’s disease or other causes of cognitive impairment based on clinical observation and cognitive screenings. The test is intended to help shorten the time to diagnosis and intervention. Neurologists and other healthcare providers can order this test to help them decide whether to refer a patient to a specialist.
According to Brian Caveney, M.D., EVP and President, Early Development Research Laboratories and Chief Medical and Scientific Officer, “Many patients experience uncertainty around Alzheimer’s disease risk, which can take months or even years to diagnose. More definitive testing, including our new ATN Profile, can provide objective insights to patients, their loved ones, and treating physicians as they navigate care and treatment.”
At Labcorp, we remain committed to improving the health and lives of those impacted by Alzheimer’s and will continue to invest in studies and drug development to treat and manage the disease.
